ALTEOGEN Inc (196170.KQ) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · South Korea · ISIN KR7196170005
ALTEOGEN Inc financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 102.85 bn KRW | 215.86 bn KRW |
| Gross profit | 64.07 bn KRW | 165.63 bn KRW |
| Operating income | 22.88 bn KRW | 106.90 bn KRW |
| EBIT | 37.29 bn KRW | 173.70 bn KRW |
| Net income | 62.25 bn KRW | 141.67 bn KRW |
| Diluted EPS – continuing operations | 1,168.07 KRW | 2,648.85 KRW |
Full history since 2014, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About ALTEOGEN Inc
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
More stocks
- MOLINA HEALTHCARE, INC. (MOH)
- Evonik Industries (EVK.DE)
- Sinotruk Hong Kong Ltd (3808.HK)
- SailPoint, Inc. (SAIL)
- Unisplendour Corp Ltd (000938.SZ)
- Skanska AB (SKA B.ST)
- U-Haul Holding Co /NV/ (UHAL)
- Hormel Foods (HRL)
- Beazley PLC (BEZ.L)
- TTM TECHNOLOGIES INC (TTMI)
- Jack Henry & Associates (JKHY)
- BIOMARIN PHARMACEUTICAL INC (BMRN)
Not investment advice. All data without warranty, price as of 15.10.2026. Details in the risk notice.